ELIXIRON IMMUNOTHERAPEUTICS HONG KONG LTD has a total of 17 patent applications. Its first patent ever was published in 2018. It filed its patents most often in WIPO (World Intellectual Property Organization), Canada and EPO (European Patent Office). Its main competitors in its focus markets pharmaceuticals and biotechnology are TENSIVE CONTROLS INC, BEIJING MABWORKS BIOTECH CO LTD and FOG PHARMACEUTICALS INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | WIPO (World Intellectual Property Organization) | 3 | |
#2 | Canada | 2 | |
#3 | EPO (European Patent Office) | 2 | |
#4 | Republic of Korea | 2 | |
#5 | United States | 2 | |
#6 | Australia | 1 | |
#7 | Brazil | 1 | |
#8 | China | 1 | |
#9 | Mexico | 1 | |
#10 | Taiwan | 1 | |
#11 | South Africa | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology |
# | Technology | |
---|---|---|
#1 | Peptides | |
#2 | Therapeutic chemical compounds | |
#3 | Medical preparations | |
#4 | Fermentation | |
#5 | Microorganisms |
# | Name | Total Patents |
---|---|---|
#1 | Ku Cheng-Lun | 13 |
#2 | Chung Pei-Han | 8 |
#3 | Shih Daw-Tsun | 8 |
#4 | Chen Hung-Kai | 8 |
#5 | Shih Han-Po | 6 |
#6 | Huang Jing-Yi | 6 |
#7 | Ding Jing-Ya | 6 |
#8 | Lin Chia-Hao | 5 |
#9 | Kuo Yi-Ting | 5 |
#10 | Ku Cheng Lun | 2 |
Publication | Filing date | Title |
---|---|---|
WO2020242950A1 | Anti-csf1r antibodies, il10 fusion proteins, and uses thereof | |
WO2020078270A1 | Antibodies to granulocyte-macrophage colony stimulating factor and uses thereof | |
AU2019243303A1 | Methods for treatment of HBV infection | |
BR112019022702A2 | range of anti-interferon antibodies and their uses. |